NEKTAR THERAPEUTICS - Common Stock, $0.0001 par value (NKTR)

CUSIP: 640268108

Q1 2021 13F Holders as of 31 Mar 2021

Holder snapshot 7 signals
Share change
-2,784,589
Put/Call ratio
96%
SEC-reported price per share
$20.00
Number of holders
224
Value change
-$52,781,602
Number of buys
90
Open additional details 1 more signal available
Number of sells
113
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
29,109,163

Security key

640268108

Report period

Q1 2021

Institutions

224

Top holders

10

Ownership snapshot

Top reported holders of NKTR - NEKTAR THERAPEUTICS - Common Stock, $0.0001 par value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Invesco Ltd.
Disclosed value leader
Invesco Ltd.
Comparable rows
0/15
Latest evidence
31 Dec 2020
13F Highest disclosed value: $602,768,000 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

Invesco Ltd. has the largest disclosed position value at $602.77M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Invesco Ltd.'s linked filing trail.
Disclosed position value Top 5
Invesco Ltd. $602.77M
FMR LLC $322.14M
PRIMECAP MANAGEMENT CO/CA/ $313.49M
BlackRock Finance, Inc. $312.43M
VANGUARD GROUP INC $276.63M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Invesco Ltd.
13F
Company
13F
—
denominator unverified
$602,768,000
35,456,949 shares
— 31 Dec 2020
FMR LLC
13F
Company
13F
—
denominator unverified
$322,145,000
18,949,685 shares
— 31 Dec 2020
PRIMECAP MANAGEMENT CO/CA/
13F
Company
13F
—
denominator unverified
$313,487,000
18,440,399 shares
— 31 Dec 2020
BlackRock Finance, Inc.
13F
Company
13F
—
denominator unverified
$312,426,000
18,378,080 shares
— 31 Dec 2020
VANGUARD GROUP INC
13F
Company
13F
—
denominator unverified
$276,634,000
16,272,585 shares
— 31 Dec 2020
WELLINGTON MANAGEMENT GROUP LLP
13F
Company
13F
—
denominator unverified
$227,674,000
13,392,612 shares
— 31 Dec 2020
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2021

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
224
Shares
169,693,928
Rows available
224
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2021 vs Q1 2026 Across Filers

Q1 2026 holders
7
Q1 2021 holders
224
Holder diff
217
Investor Q1 2026 Shares Q1 2021 Shares Share Diff Share Chg % Q1 2026 value Q1 2021 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .